Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology, immunotherapy and rare-disease therapeutics. Company updates cover its internal drug pipeline, orphan oncology programs, antisense and small molecule injectable drug candidates, and partnerships or joint ventures used to license and co-develop selected candidates.
Recurring OTLC news also includes the PDAOAI AI platform for research, biomarker discovery, regulatory processes and GMP-compliant robotics, the company's 45% interest in GMP Bio and related Sapu Bio and Sapu Nano programs, and completed portfolio actions such as field-specific monetization of N2B nose-to-brain delivery assets.
Oncotelic Therapeutics (OTCQB:OTLC), formerly known as Mateon Therapeutics, announced on March 30, 2021, that the Financial Industry Regulatory Authority (FINRA) has approved its name and ticker symbol change. The new ticker symbol, effective immediately, is OTLC, replacing MATN. This follows a corporate action approved by shareholders in August 2020, which included the name change finalized in November 2020. Oncotelic focuses on developing RNA therapeutics and small molecule drugs targeting cancer and infectious diseases, particularly emphasizing rare pediatric cancers.